Novo Nordisk (NVO) announced a series of initiatives to support patient access to authentic, FDA-approved Wegovy – semaglutide – injection 2.4 mg. as the FDA grace period for mass compounding of “semaglutide” expires. A one-time offer for self-paying patients new to Wegovy is now available for a limited time, through June 30. This one-time offer is intended to help patients who have previously been prescribed unapproved or illicit “semaglutide” drugs and are seeking access to FDA-approved Wegovy. Novo Nordisk is offering self-paying patients who are new to Wegovy their first month of medicine for $199 through June 30. For subsequent months, self-pay patients will pay $499 per month. The company continues to invest in actively correcting misinformation and educating communities about the risks of knockoff “semaglutide”. The campaign emphasizes the importance of using FDA-approved treatments and directs patients to trusted resources. Now that the FDA’s grace period has ended, any entity that mass produces or sells knockoff “semaglutide” is breaking the law and putting patient safety at risk. Nearly all “semaglutide” used in compounding is manufactured by Chinese and other foreign suppliers. The FDA has never authorized or approved the manufacturing processes used by any of these foreign suppliers, nor has the FDA reviewed or authorized the quality of the “semaglutide” they produce. Novo Nordisk will continue pursuing legal action to protect patients from the risks posed by unapproved knockoff drugs and foreign illicit active pharmaceutical ingredients.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Sector Spotlight: Trump executive order targets drug prices
- Charter to combine with Cox, Take-Two reports mixed Q4 results: Morning Buzz
- Novo Nordisk Ousts CEO After 50% Drop in NVO Stock
- Morning Movers: Charter to combine with Cox Communication
- Novo Nordisk CEO Lars Fruergaard Jørgensen to Step Down Amid Market Challenges
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue